KYMRIAH

Google image searchProduct monograph

Active ingredient

tisagenlecleucel, 600000000 CELLS

DIN: 02480514

Dosage form(s): SUSPENSION

Route(s) of administration: INTRAVENOUS

Schedule: Prescription / Schedule D

Company: NOVARTIS PHARMACEUTICALS CANADA INC

Date: 24-MAY-2019

ATC:

• L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
• L01X — OTHER ANTINEOPLASTIC AGENTS (ATC, ATC/DDD)
• L01XL — Antineoplastic cell and gene therapy (ATC, ATC/DDD)
• L01XL04 — TISAGENLECLEUCEL (ATC/DDD)

Pharmaceutical standard: MFR

External Links for Kymriah

Search on Google

• Kymriah side effects
• Kymriah dosage
• tisagenlecleucel side effects
• tisagenlecleucel dosage

Novartis Pharmaceuticals Canada Inc

Go to Novartis website to see drug product details. Sometimes you can find kymriah photos and/or monograph. If you are a healthcare professional, you may need to enter your license number.